GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neon Therapeutics Inc (NAS:NTGN) » Definitions » Price-to-Tangible-Book

Neon Therapeutics (Neon Therapeutics) Price-to-Tangible-Book : 6.16 (As of May. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Neon Therapeutics Price-to-Tangible-Book?

As of today (2024-05-08), Neon Therapeutics's share price is $3.07. Neon Therapeutics's Tangible Book per Share of Mar. 2020 for the quarter that ended in Mar. 2020 was $0.50. Hence, Neon Therapeutics's Price to Tangible Book Ratio of today is 6.16.

The historical rank and industry rank for Neon Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

NTGN's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.73
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, Neon Therapeutics's share price is $3.07. Neon Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2020 was $0.50. Hence, Neon Therapeutics's P/B Ratio of today is 6.16.


Neon Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Neon Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neon Therapeutics Price-to-Tangible-Book Chart

Neon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Price-to-Tangible-Book
- - 1.41 1.15

Neon Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.23 2.16 1.08 1.15 5.30

Competitive Comparison of Neon Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Neon Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neon Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neon Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Neon Therapeutics's Price-to-Tangible-Book falls into.



Neon Therapeutics Price-to-Tangible-Book Calculation

Neon Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2020 )
=3.07/0.498
=6.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Neon Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Neon Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Neon Therapeutics (Neon Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
40 Erie Street, Suite 110, Cambridge, MA, USA, 02139
Neon Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Executives
Cary Pfeffer director C/O ELEVEN BIOTHERAPEUTICS, 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142
Jolie Siegel officer: VP, General Counsel C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Robert Kamen director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, BOSTON MA 02210
Meryl Zausner director C/O NEON THERAPEUTICS, INC., 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Eric S Lander director 415 MAIN STREET, CAMBRIDGE MA 02142
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Robert I Tepper director, 10 percent owner 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Robert B Bazemore director 33 HAYDEN AVE, LEXINGTON MA 02421
Richard Gaynor officer: President of R&D C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Access Industries, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Management, Llc other: Affiliate of 10% Owner 730 FIFTH AVENUE, NEW YORK NY 10019
Access Industries Holdings Llc 10 percent owner C/O ACCESS INDUSTRIES MANAGEMENT, LLC., 730 FIFTH AVENUE, 20TH FLOOR, NEW YORK NY 10019
Clal Biotechnology Industries Ltd. other: See Remarks 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik other: Affiliate of 10% Owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019